Solving the Pharma Talent Puzzle in China
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Yunnan Baiyao Group Co., Ltd. manufactures and sells Chinese pharmaceutical products in China and internationally. The company provides Yunnan Baiyao series of products, including powders, capsules, plasters, woundplasts, and aerosols for activating blood circulation, dispersing blood stasis, reducing swelling, and relieving pain, as well as to treat traumatic injuries, rheumatic paralysis, pains in bones, muscle aches, and cold injuries. It also offers phytobiological medicines in the forms of oral liquids, tablets, powders, flower-leave granules, and capsules; and health products consisting of toothpastes, itching-relieving and smoothing essential skin cares, shower and foot bath effervescent tablets, shoe disinfectant and deodorize aerosols, and first aid kits. In addition, the company provides medicines, such as paracetamol, aminophenazone, caffeine, and chlorphenamine maleate tablets, as well as oxytetracycline tablets and norfloxacin capsules. Yunnan Baiyao Group Co., Ltd. is based in Kunming, China.
While China may be grappling with an economic slowdown and escalating geopolitical tensions, it remains the world’s second largest pharma market and a country that boasts an extraordinarily dynamic life…
Beyond political, cultural, economic, and linguistic concerns, the sheer pace of Chinese pharma’s development makes it challenging for international observers to fully grasp the sector’s intricacies, challenges, and numerous opportunities.…
2024 marks 30 years for Takeda in China, and the company has been outstripping the overall market to grow by double-digits in the country since 2020. Sean Shan discusses how…
Shawn Leung, CEO of Chinese biotech SinoMab, discusses the”Biotech 3.0″ philosophy that characterizes the company as it strives for both scientific innovation and differentiation. He highlights SinoMab’s atopic dermatitis and…
Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global…
Jens Ewert, Life Science and Health Care Industry Leader at Deloitte China, provides an in-depth analysis of the development of China’s healthcare landscape over the previous past four years. Ewert…
Deng Haoqing, President and General Manager of Chiesi China, explores the company’s strategic growth in one of the world’s most dynamic healthcare markets. Deng discusses the alignment of Chiesi’s “AIR,…
Jun Liu, CEO & Executive Board Director of BioDlink, defines and explores the company’s strategic focus on antibody drug conjugates (ADCs), their global expansion plans, and role as a leading…
Vivian Zhang, Managing Director and General Manager of Merck China Healthcare, shares insights into the market’s strategic importance to the company and its current priorities in the country. She discusses…
EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the new drugs added to the country’s national health insurance with AstraZeneca’s breast cancer blockbuster,…
Vincent Chan, VP and GM of bioMérieux Greater China, shares insights into how the microbiology diagnostics company’s presence has evolved in China over the course of 30 years to today…
See our Cookie Privacy Policy Here
